A state-of-the-art LEAN-optimized laboratory is being built close to the current site, which will bring a fourfold increase in capacity compared to the current laboratory space. The company, which is part of the GBA Group, relies on state-of-the-art digital processes to increase the efficiency of laboratory workflows and continue to optimally meet customer requirements for faster throughput times.

Lavetan would like to extend a warm welcome to Mathieux de Buy Wenniger, our new Analytical Service Manager. He was previously employed at Kemin Industries, providing support to the United Nations (UN) World Food Program Department of Food Safety and Quality. His wide-ranging experience and wealth of knowledge will be put to excellent use at Lavetan. Together, we will be able to resolve chemical issues facing the market faster and better than ever before. We spoke to Mathieux about his professional background.

With ISO 10993-1:2018 and ISO 10993-18:2020 the importance of material characterization by chemical analysis in the course of biological evaluation of medical devices has greatly increased.

The performance of the cytotoxicity test serves the medical device manufacturer to prove the biocompatibility of its product, e.g. in the context of a CE marking, and to identify biological hazards and to assess the risk of the product already during product development.

On Sept. 26, 2023, Dr. Sabine Gorynia, EVP GBA Group Pharma & Medical Devices, Torben Giese, Chief Strategy Officer GBA Group, and Felix Bunde, Managing Director GBA MDS, visited the new colleagues at ICCR Roßdorf GmbH.